eFFECTOR Therapeutics Past Earnings Performance
Past criteria checks 0/6
eFFECTOR Therapeutics's earnings have been declining at an average annual rate of -43.2%, while the Biotechs industry saw earnings growing at 19% annually. Revenues have been declining at an average rate of 76.6% per year.
Key information
-43.2%
Earnings growth rate
80.6%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | -76.6% |
| Return on equity | -4,187.5% |
| Net Margin | n/a |
| Last Earnings Update | 31 Mar 2024 |
Revenue & Expenses Breakdown
How eFFECTOR Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 0 | -35 | 11 | 0 |
| 31 Dec 23 | 0 | -36 | 11 | 0 |
| 30 Sep 23 | 1 | -36 | 11 | 0 |
| 30 Jun 23 | 2 | -37 | 12 | 0 |
| 31 Mar 23 | 4 | -36 | 12 | 0 |
| 31 Dec 22 | 4 | -23 | 13 | 0 |
| 30 Sep 22 | 3 | 6 | 16 | 0 |
| 30 Jun 22 | 3 | 24 | 17 | 0 |
| 31 Mar 22 | 1 | 25 | 16 | 0 |
| 31 Dec 21 | 1 | 16 | 13 | 0 |
| 30 Sep 21 | 1 | -4 | 8 | 0 |
| 30 Jun 21 | 1 | -20 | 5 | 0 |
| 31 Mar 21 | 16 | -7 | 5 | 0 |
| 31 Dec 20 | 42 | 0 | 4 | 0 |
Quality Earnings: EFTR is currently unprofitable.
Growing Profit Margin: EFTR is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: EFTR is unprofitable, and losses have increased over the past 5 years at a rate of 43.2% per year.
Accelerating Growth: Unable to compare EFTR's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: EFTR is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (13.6%).
Return on Equity
High ROE: EFTR has a negative Return on Equity (-4187.55%), as it is currently unprofitable.